Moximed has implanted the first patient with its KineSpring system in a prospective, single-arm clinical US study.

The study, named SOAR, will enroll 30 patients to evaluate the safety and efficacy of the medical spring system in the treatment of knee osteoarthritis.

The CE-marked KineSpring system, which is implanted in the subcutaneous tissue alongside the joint, works by unloading the weight on the diseased knee joint.

Oregon Health & Science University sports medicine director, orthopedic surgery associate professor and study principal investigator Dennis Crawford said previous clinical studies conducted on KineSpring system in Europe and Australia have shown favorable results.

"My Co-investigators and I are encouraged by this experience and believe the KineSpring System could prove to be an effective treatment option in active individuals, with early knee osteoarthritis, who are interested in a procedure that is less invasive than joint replacement surgery," Crawford added.

Moximed president and CEO Kevin Sidow said, "The KineSpring System is already commercialized in the major European markets, and we look forward to seeing the results and progressing with the product’s development in the US."